Breaking News Instant updates and real-time market news.

ACOR

Acorda Therapeutics

$25.10

-0.5 (-1.95%)

16:07
02/15/18
02/15
16:07
02/15/18
16:07

Acorda Therapeutics upgraded to Overweight from Neutral at Piper Jaffray

  • 15

    Feb

  • 15

    Feb

ACOR Acorda Therapeutics
$25.10

-0.5 (-1.95%)

11/21/17
JANY
11/21/17
NO CHANGE
Target $17
JANY
Neutral
Acorda could be worth $17-$27 in takeover, says Janney Capital
After Acorda Therapeutics announced that it is discontinuing development of tozadenant, an investigational treatment for Parkinson's disease, Janney Capital analyst Ken Trbovich said he believes a sale process appears necessary to protect shareholders from downside that he sees if Acorda remains independent. While the stock may only be worth $10-$11 if Acorda stays independent, it could be worth $17-$27 in a takeout scenario, estimated Trbovich, who maintains a Neutral rating and $17 fair value estimate on Acorda shares.
11/28/17
PIPR
11/28/17
INITIATION
Target $22
PIPR
Neutral
Acorda Therapeutics assumed with a Neutral at Piper Jaffray
Piper Jaffray analyst Charles Duncan assumed coverage of Acorda Therapeutics with a Neutral rating and $22 price target. The analyst believes Inbrija could be a best-in-class acute treatment with $800M in peak U.S. sales. He's looking for clinical and regulatory progress "which re-establishes conviction in Acorda's execution."
01/31/18
JANY
01/31/18
NO CHANGE
JANY
Neutral
Competitor Phase 3 'takes some shine off' Acorda Therapeutics, says Janney Capital
Janney Capital analyst Ken Trbovich notes that Sunovion Pharmaceuticals, a wholly owned U.S.-based subsidiary of Sumitomo Dainippon Pharma, reported positive top-line results from its Phase 3 trial of APL-130277 for treating OFF-rescue in Parkinson's Disease patients. While the respective Phase 3 studies were not head-to-head, it would appear APL-130277 may be the more potent OFF rescue treatment, with the trade-off being higher rates unpleasant side effects such as nausea and dizziness, the analyst notes. Trbovich believes this could take some of the luster off perceived M&A value of Acorda Therapeutics, but it is unlikely to eliminate interest. He reiterates a Neutral rating on Acorda Therapeutics' shares.
02/05/18
JEFF
02/05/18
NO CHANGE
Target $25
JEFF
Hold
Acorda remains takeover candidate after competitor data, says Jefferies
Jefferies analyst Michael Yee believes the positive Phase III topline results from Acorda Therapeutics (ACOR) competitor Sunovion for APL-130277 in Parkinson's patients came in as expected. While APL-130277 data compares favorably over Inbrija's 3.92 point difference at week 12, Yee cautions to compare directly head-to-head since patient baseline characteristics could be different. Acorda remains a "reasonably likely" acquisition candidate in 2018 given its $300M-$500M-plus Parkinson's asset Inbrija, Yee tells investors in a research note. The analyst does not think Biogen (BIIB) should buy the company, but sees other potential suitors in AbbVie (ABBV), Allergan (AGN), Mitsubishi, Roche (RHHBY) and Shire (SHPG). He believes a takeover price could be north of $2B. Yee keeps a Hold rating on Acorda with a $25 price target.

TODAY'S FREE FLY STORIES

DRGDF

Detour Gold

$0.00

(0.00%)

07:19
12/14/18
12/14
07:19
12/14/18
07:19
Downgrade
Detour Gold rating change  »

Detour Gold downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MCD

McDonald's

$186.53

2.99 (1.63%)

, YUM

Yum! Brands

$93.49

3.02 (3.34%)

07:19
12/14/18
12/14
07:19
12/14/18
07:19
Recommendations
McDonald's, Yum! Brands analyst commentary  »

JPMorgan calls…

MCD

McDonald's

$186.53

2.99 (1.63%)

YUM

Yum! Brands

$93.49

3.02 (3.34%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NNN

National Retail Properties

$50.86

0.94 (1.88%)

07:18
12/14/18
12/14
07:18
12/14/18
07:18
Downgrade
National Retail Properties rating change  »

National Retail…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DRGDF

Detour Gold

$0.00

(0.00%)

07:16
12/14/18
12/14
07:16
12/14/18
07:16
Downgrade
Detour Gold rating change  »

Detour Gold downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BLCM

Bellicum Pharmaceuticals

$3.60

-0.155 (-4.13%)

07:15
12/14/18
12/14
07:15
12/14/18
07:15
Hot Stocks
Bellicum Pharmaceuticals reports data from BPX-601 at ESMO-IO »

Bellicum Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

THG

Hanover Insurance

$109.52

-0.68 (-0.62%)

07:14
12/14/18
12/14
07:14
12/14/18
07:14
Conference/Events
Hanover Insurance management to meet with Buckingham »

Meeting to be held in San…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Dec

  • 19

    Dec

BHC

Bausch Health

$23.65

-0.47 (-1.95%)

07:12
12/14/18
12/14
07:12
12/14/18
07:12
Upgrade
Bausch Health rating change  »

Bausch Health upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Feb

  • 25

    Feb

IDRA

Idera Pharmaceuticals

$6.60

-0.06 (-0.90%)

07:10
12/14/18
12/14
07:10
12/14/18
07:10
Hot Stocks
Idera Pharmaceuticals presents data from Phase 2 expansion of ILUMMINATE-204 »

Idera Pharmaceuticals has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Dec

RBA

Ritchie Bros.

$32.39

-0.28 (-0.86%)

07:08
12/14/18
12/14
07:08
12/14/18
07:08
Hot Stocks
Ritchie Bros. sells C$639M+ of equipment in Edmonton auction »

Ritchie Bros. held its…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SBUX

Starbucks

$66.90

0.8 (1.21%)

07:07
12/14/18
12/14
07:07
12/14/18
07:07
Recommendations
Starbucks analyst commentary  »

Starbucks story regaining…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Dec

VLKAY

Volkswagen

$0.00

(0.00%)

, DDAIF

Daimler AG

$0.00

(0.00%)

07:07
12/14/18
12/14
07:07
12/14/18
07:07
Hot Stocks
EU passenger car registrations down 8.0% in November »

In November, passenger…

VLKAY

Volkswagen

$0.00

(0.00%)

DDAIF

Daimler AG

$0.00

(0.00%)

NSANY

Nissan

$0.00

(0.00%)

TM

Toyota

$120.89

-1.04 (-0.85%)

F

Ford

$8.50

-0.135 (-1.56%)

HMC

Honda

$27.23

-0.03 (-0.11%)

GM

General Motors

$35.11

-0.58 (-1.63%)

FCAU

Fiat Chrysler

$15.67

-0.18 (-1.14%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Jan

  • 23

    Jan

  • 25

    Apr

  • 24

    Jul

  • 23

    Oct

CPRX

Catalyst Pharmaceuticals

$2.47

0.075 (3.14%)

07:06
12/14/18
12/14
07:06
12/14/18
07:06
Recommendations
Catalyst Pharmaceuticals analyst commentary  »

Catalyst Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

REXR

Rexford Industrial

$31.42

0.09 (0.29%)

07:06
12/14/18
12/14
07:06
12/14/18
07:06
Hot Stocks
Rexford Industrial acquires industrial property for $18.2M »

Rexford Industrial Realty…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

COST

Costco

$226.41

-1.41 (-0.62%)

07:05
12/14/18
12/14
07:05
12/14/18
07:05
Recommendations
Costco analyst commentary  »

Costco price target cut…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

07:05
12/14/18
12/14
07:05
12/14/18
07:05
General news
Futures lower after underwhelming Chinese data »

Stock futures are…

LPTX

Leap Therapeutics

$2.85

-0.27 (-8.65%)

07:04
12/14/18
12/14
07:04
12/14/18
07:04
Hot Stocks
Leap Therapeutics presents final data from the Phase I/II study of DKN-01 »

Leap provided the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CIEN

Ciena

$34.90

2.765 (8.60%)

07:04
12/14/18
12/14
07:04
12/14/18
07:04
Recommendations
Ciena analyst commentary  »

Ciena price target raised…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LPTX

Leap Therapeutics

$2.85

-0.27 (-8.65%)

07:03
12/14/18
12/14
07:03
12/14/18
07:03
Hot Stocks
Leap Therapeutics presents TRX518 data at ESMO »

Leap Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TTD

Trade Desk

$139.16

-4.28 (-2.98%)

07:03
12/14/18
12/14
07:03
12/14/18
07:03
Recommendations
Trade Desk analyst commentary  »

Trade Desk price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BCEI

Bonanza Creek

$25.01

-0.26 (-1.03%)

07:02
12/14/18
12/14
07:02
12/14/18
07:02
Initiation
Bonanza Creek initiated  »

Bonanza Creek initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SBUX

Starbucks

$66.90

0.8 (1.21%)

07:00
12/14/18
12/14
07:00
12/14/18
07:00
Recommendations
Starbucks analyst commentary  »

Starbucks can sustain…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Dec

07:00
12/14/18
12/14
07:00
12/14/18
07:00
General news
FX Update: The dollar has traded firmer »

FX Update: The dollar has…

TCBI

Texas Capital

$53.03

-2.42 (-4.36%)

06:57
12/14/18
12/14
06:57
12/14/18
06:57
Initiation
Texas Capital initiated  »

Texas Capital initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

  • 29

    Jan

GCO

Genesco

$42.10

-2.39 (-5.37%)

06:57
12/14/18
12/14
06:57
12/14/18
06:57
Hot Stocks
Genesco increases stock repurchase program to $125M »

The company also…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KAMN

Kaman

$56.89

-0.18 (-0.32%)

06:55
12/14/18
12/14
06:55
12/14/18
06:55
Downgrade
Kaman rating change  »

Kaman downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.